GALNT14 and hepatocellular carcinoma: Using genome-wide association studies followed by prospective validation, germline-derived genetic variants of the polypeptide N-acetylgalactosaminyltransferase 14 (GALNT14) gene have been identified as predictors of response in patients with HCC receiving chemotherapy [6].